Evaluating whether Ocugen represents a sound investment depends heavily on an investor's personal risk tolerance, capital horizon, and appetite for micro-cap biotechnology equities. Bullish market participants view its innovative gene-agnostic therapy platform and supportive institutional analyst targets as strong drivers for long-term capital appreciation. Conversely, conservative investors point to historical share volatility, ongoing operational cash burn, and the lack of commercial product revenues as factors requiring extreme caution and thorough fundamental due diligence.